The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma
Baxter MA1, Glen H1, Evans TR1,2. Future Oncol. 2018 May 22. doi: 10.2217/fon-2017-0689. [Epub ahead of print]
Author information
1
Beatson West of Scotland Cancer Centre, Glasgow, UK.
2
The Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for approximately 90% of cases. Patients often present at an advanced stage when treatment options are limited. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been the first-line treatment in this setting for almost a decade. Several subsequent targeted therapies have failed to demonstrate significant improvement in survival. The results of the REFLECT study suggest that lenvatinib, a multikinase inhibitor, may have promised as a first-line treatment in patients with advanced HCC. This article will review the development of lenvatinib and the evidence behind its potential use in patients with advanced HCC.